Back to News
Market Impact: 0.25
One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
One04 Therapeutics launched following encouraging interim Phase 1 results for CPV-104. The company plans to broaden clinical development into kidney diseases and dry age-related macular degeneration, expanding the potential addressable patient population. The update is an early-stage clinical and pipeline-positive catalyst, although efficacy and safety details were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Intel’s stock crashes, knocking $12B from government’s stake
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Backbone of a beast – charting Nvidia's rise to networking titan
- Nasdaq futures sink 2.3% as Amazon, Intel and Alphabet send AI jitters through stocks